# Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage:

> **NCT01030770** · PHASE2,PHASE3 · COMPLETED · sponsor: **King's College Hospital NHS Trust** · enrollment: 25 (actual)

## Conditions studied

- Diabetes Complications

## Interventions

- **DRUG:** Ranibizumab
- **DRUG:** 0.9% Sodium Chloride

## Key facts

- **NCT ID:** NCT01030770
- **Lead sponsor:** King's College Hospital NHS Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2015-12
- **Final completion:** 2016-05
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01030770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01030770, "Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage:". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01030770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*